Caveolins in the development and diseases of musculoskeletal system

Cancer Letters

Volumn 284, Issue 2, 2009, Pages 113-121

  Serra, Massimo ^a   Scotlandi, Katia ^a  

^a Laboratory of Oncologic Research   (Italy)

Author keywords

Caveolin; Muscle differentiation; Osteoblast differentiation; Sarcoma

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

BONE CELL; BONE TUMOR; CELL DIFFERENTIATION; GENE MUTATION; HUMAN; MULTIDRUG RESISTANCE; MUSCLE CELL; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOSARCOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

EID: 69749116814     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.016     Document Type: Review

References (64)

1. Gumbleton M., Abulrob A.G., and Campbell L. Caveolae: an alternative membrane transport compartment. Pharmaceutical Research 17 (2000) 1035-1048
2. Williams T.M., and Lisanti M.P. The caveolin proteins. Genome Biology 5 (2004) 214
3. Burgermeister E., Liscovitch M., Rocken C., Schmid R.M., and Ebert M.P. Caveats of caveolin-1 in cancer progression. Cancer Letters 268 (2008) 187-201
4. Scherer P.E., Tang Z., Chun M., Sargiacomo M., Lodish H.F., and Lisanti M.P. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. The Journal of Biological Chemistry 270 (1995) 16395-16401
5. Scherer P.E., Okamoto T., Chun M., Nishimoto I., Lodish H.F., and Lisanti M.P. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 131-135
6. Tang Z., Scherer P.E., Okamoto T., Song K., Chu C., Kohtz D.S., Nishimoto I., Lodish H.F., and Lisanti M.P. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. The Journal of Biological Chemistry 271 (1996) 2255-2261
7. Schubert W., Sotgia F., Cohen A.W., Capozza F., Bonuccelli G., Bruno C., Minetti C., Bonilla E., Dimauro S., and Lisanti M.P. Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. The American Journal of Pathology 170 (2007) 316-333
8. Williams T.M., and Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. American Journal of Physiology 288 (2005) C494-506
9. Head B.P., and Insel P.A. Do caveolins regulate cells by actions outside of caveolae?. Trends in Cell Biology 17 (2007) 51-57
10. Cohen A.W., Hnasko R., Schubert W., and Lisanti M.P. Role of caveolae and caveolins in health and disease. Physiological Reviews 84 (2004) 1341-1379
11. Patel H.H., Murray F., and Insel P.A. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annual Review of Pharmacology and Toxicology 48 (2008) 359-391
12. Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Molecular Interventions 3 (2003) 445-464
13. Solomon K.R., Danciu T.E., Adolphson L.D., Hecht L.E., and Hauschka P.V. Caveolin-enriched membrane signaling complexes in human and murine osteoblasts. Journal of Bone and Mineral Research 15 (2000) 2380-2390
14. Solomon K.R., Adolphson L.D., Wank D.A., McHugh K.P., and Hauschka P.V. Caveolae in human and murine osteoblasts. Journal of Bone and Mineral Research 15 (2000) 2391-2401
15. Lofthouse R.A., Davis J.R., Frondoza C.G., Jinnah R.H., Hungerford D.S., and Hare J.M. Identification of caveolae and detection of caveolin in normal human osteoblasts. The Journal of Bone and Joint Surgery 83 (2001) 124-129
16. Song K.S., Scherer P.E., Tang Z., Okamoto T., Li S., Chafel M., Chu C., Kohtz D.S., and Lisanti M.P. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. The Journal of Biological Chemistry 271 (1996) 15160-15165
17. Parton R.G., Way M., Zorzi N., and Stang E. Caveolin-3 associates with developing T-tubules during muscle differentiation. The Journal of Cell Biology 136 (1997) 137-154
18. Capozza F., Cohen A.W., Cheung M.W., Sotgia F., Schubert W., Battista M., Lee H., Frank P.G., and Lisanti M.P. Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells. American Journal of Physiology 288 (2005) C677-691
19. Volonte D., Liu Y., and Galbiati F. The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB Journal 19 (2005) 237-239
20. Carlson B.M., Carlson J.A., Dedkov E.I., and McLennan I.S. Concentration of caveolin-3 at the neuromuscular junction in young and old rat skeletal muscle fibers. Journal of Histochemistry and Cytochemistry 51 (2003) 1113-1118
21. Nixon S.J., Wegner J., Ferguson C., Mery P.F., Hancock J.F., Currie P.D., Key B., Westerfield M., and Parton R.G. Zebrafish as a model for caveolin-associated muscle disease; caveolin-3 is required for myofibril organization and muscle cell patterning. Human Molecular Genetics 14 (2005) 1727-1743
22. Woodman S.E., Sotgia F., Galbiati F., Minetti C., and Lisanti M.P. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62 (2004) 538-543
23. Lorenzoni P.J., Scola R.H., Vieira N., Vainzof M., Carsten A.L., and Werneck L.C. A novel missense mutation in the caveolin-3 gene in rippling muscle disease. Muscle and Nerve 36 (2007) 258-260
24. Reijneveld J.C., Ginjaar I.B., Frankhuizen W.S., and Notermans N.C. CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle and Nerve 34 (2006) 656-658
25. Traverso M., Gazzerro E., Assereto S., Sotgia F., Biancheri R., Stringara S., Giberti L., Pedemonte M., Wang X., Scapolan S., et al. Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro. Laboratory Investigation; A Journal of Technical Methods and Pathology 88 (2008) 275-283
26. Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., Masetti E., Mazzocco M., Egeo A., Donati M.A., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nature Genetics 18 (1998) 365-368
27. Galbiati F., Volonte D., Minetti C., Chu J.B., and Lisanti M.P. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. The Journal of Biological Chemistry 274 (1999) 25632-25641
28. Couchoux H., Allard B., Legrand C., Jacquemond V., and Berthier C. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells. The Journal of Physiology 580 (2007) 745-754
29. Smythe G.M., Eby J.C., Disatnik M.H., and Rando T.A. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. Journal of Cell Science 116 (2003) 4739-4749
30. Hernandez-Deviez D.J., Martin S., Laval S.H., Lo H.P., Cooper S.T., North K.N., Bushby K., and Parton R.G. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Human Molecular Genetics 15 (2006) 129-142
31. Ohsawa Y., Hagiwara H., Nakatani M., Yasue A., Moriyama K., Murakami T., Tsuchida K., Noji S., and Sunada Y. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. The Journal of Clinical Investigation 116 (2006) 2924-2934
32. Bonilla E., Fischbeck K., and Schotland D.L. Freeze-fracture studies of muscle caveolae in human muscular dystrophy. The American Journal of Pathology 104 (1981) 167-173
33. Vaghy P.L., Fang J., Wu W., and Vaghy L.P. Increased caveolin-3 levels in mdx mouse muscles. FEBS Letters 431 (1998) 125-127
34. Gervasio O.L., Whitehead N.P., Yeung E.W., Phillips W.D., and Allen D.G. TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy. Journal of Cell Science 121 (2008) 2246-2255
35. Sawada N., Taketani Y., Amizuka N., Ichikawa M., Ogawa C., Nomoto K., Nashiki K., Sato T., Arai H., Isshiki M., et al. Caveolin-1 in extracellular matrix vesicles secreted from osteoblasts. Bone 41 (2007) 52-58
36. Rubin J., Schwartz Z., Boyan B.D., Fan X., Case N., Sen B., Drab M., Smith D., Aleman M., Wong K.L., et al. Caveolin-1 knockout mice have increased bone size and stiffness. Journal of Bone and Mineral Research 22 (2007) 1408-1418
37. Jung S.Y., Kwak J.O., Kim H.W., Kim D.S., Ryu S.D., Ko C.B., and Cha S.H. Calcium sensing receptor forms complex with and is up-regulated by caveolin-1 in cultured human osteosarcoma (Saos-2) cells. Experimental and Molecular Medicine 37 (2005) 91-100
38. Kameda T., Mano H., Yamada Y., Takai H., Amizuka N., Kobori M., Izumi N., Kawashima H., Ozawa H., Ikeda K., et al. Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochemical and Biophysical Research Communications 245 (1998) 419-422
39. Luegmayr E., Glantschnig H., Wesolowski G.A., Gentile M.A., Fisher J.E., Rodan G.A., and Reszka A.A. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death and Differentiation 11 Suppl. 1 (2004) S108-S1118
40. Wiechen K., Sers C., Agoulnik A., Arlt K., Dietel M., Schlag P.M., and Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. The American Journal of Pathology 158 (2001) 833-839
41. Bayer-Garner I., Morgan M., and Smoller B.R. Caveolin expression is common among benign and malignant smooth muscle and adipocyte neoplasms. Modern Pathology 15 (2002) 1-5
42. Cantiani L., Manara M.C., Zucchini C., De Sanctis P., Zuntini M., Valvassori L., Serra M., Olivero M., Di Renzo M.F., Colombo M.P., et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Research 67 (2007) 7675-7685
43. Zucchini C., Bianchini M., Valvassori L., Perdichizzi S., Benini S., Manara M.C., Solmi R., Strippoli P., Picci P., Carinci P., et al. Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone 34 (2004) 672-679
44. Manara M.C., Bernard G., Lollini P.L., Nanni P., Zuntini M., Landuzzi L., Benini S., Lattanzi G., Sciandra M., Serra M., et al. CD99 acts as an oncosuppressor in osteosarcoma. Molecular Biology of the Cell 17 (2006) 1910-1921
45. Hu D., Man Z., Wang P., Tan X., Wang X., Takaku S., Hyuga S., Sato T., Yao X., Yamagata S., et al. Ganglioside GD1a negatively regulates matrix metalloproteinase-9 expression in mouse FBJ cell lines at the transcriptional level. Connective Tissue Research 48 (2007) 198-205
46. Tirado O.M., Mateo-Lozano S., Villar J., Dettin L.E., Llort A., Gallego S., Ban J., Kovar H., and Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Research 66 (2006) 9937-9947
47. Bailey K.M., and Liu J. Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. The Journal of Biological Chemistry 283 (2008) 13714-13724
48. Fine S.W., Lisanti M.P., Argani P., and Li M. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma. Applied Immunohistochemistry and Molecular Morphology 13 (2005) 231-236
49. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews 2 (2002) 48-58
50. Shatz M., and Liscovitch M. Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins?. Leukemia Research 28 (2004) 907-908
51. Lavie Y., Fiucci G., and Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. The Journal of Biological Chemistry 273 (1998) 32380-32383
52. Lavie Y., and Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconjugate Journal 17 (2000) 253-259
53. Pang A., Au W.Y., and Kwong Y.L. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leukemia Research 28 (2004) 973-977
54. Lavie Y., Fiucci G., and Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Advanced Drug Delivery Reviews 49 (2001) 317-323
55. Zhu H., Cai C., and Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Letters 576 (2004) 369-374
56. Cai C., and Chen J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. International Journal of Cancer 111 (2004) 522-529
57. Cai C., Zhu H., and Chen J. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochemical and Biophysical Research Communications 320 (2004) 868-874
58. Barakat S., Demeule M., Pilorget A., Regina A., Gingras D., Baggetto L.G., and Beliveau R. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. Journal of Neurochemistry 101 (2007) 1-8
59. Belanger M.M., Roussel E., and Couet J. Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest 125 (2004) 106S
60. Hinrichs J.W., Klappe K., Hummel I., and Kok J.W. ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells. The Journal of Biological Chemistry 279 (2004) 5734-5738
61. Selga E., Morales C., Noe V., Peinado M.A., and Ciudad C.J. Role of Caveolin 1, E-Cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Medical Genomics 1 (2008) 35
62. Nakamura M., Nakatani K., Uzawa K., Ono K., Uesugi H., Ogawara K., Shiiba M., Bukawa H., Yokoe H., Wada T., et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncology Reports 14 (2005) 1281-1286
63. Nakatani K., Wada T., Nakamura M., Uzawa K., Tanzawa H., and Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology 131 (2005) 445-452
64. Pakos E.E., and Ioannidis J.P. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma, a meta-analysis. Cancer 98 (2003) 581-589